A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis (opens ClinicalTrials.gov)
- Sponsor
- Rein Therapeutics
- Enrolment
- 120
- Started
- 2026-02-02
- Last update
- 2026-11-03
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: LTI-03, Dry Powder Inhaler, Placebo